GVHD is one of the most frequent complications of BMT and recently nephrotic syndrome (NS) has been described as a manifestation of chronic GVHD. Here, we present an AA patient who developed NS 1 year after BMT when cyclosporine was stopped. Renal biopsy showed focal sclerosis associated with membranous deposits. He also had other clinical manifestations of chronic GVHD: sicca-like syndrome and colestasis. After 15 days of CsA therapy, he experienced a remarkable improvement in the NS and GVHD as a whole. We comment on immunological mechanisms that could be involved in the pathogenesis of this manifestation.
Chronic graft-versus-host disease (GVHD) is one of the most frequent complications after bone marrow transplantation (BMT). It is immune-mediated and involves autoantibodies generated by T-lymphocyte donor reactivity to major histocompatibility complex (MHC) minor antigens. 1, 2 Nephrotic syndrome (NS) has been described as one of the clinical forms of chronic GVHD or as part of this clinical syndrome. Membranous glomerulonephritis has been found in the majority of patients and one case has described minimal change nephrotic syndrome. [3] [4] [5] [6] [7] Here, we present a typical case of NS, with an unusual morphological feature in the setting of well-documented chronic GVHD. A 26-year-old white man with AAS underwent a related identical HLA BMT in January 1994. He received ATG (90 mg/kg) and cyclophosphamide (200 mg/kg), as conditioning and short-term MTX plus cyclosporine (CsA) as GVHD prophylaxis, without any evidence of acute or chronic GVHD. CsA was tapered 180 days after BMT and withdrawn after 1 year. conjunctival hyperemia and a month later, he developed clinical nephrotic syndrome with a 24-h urine protein of 3.64 g/dl, serum albumin of 1.4 and antinuclear antibody titer of 1:160 with normal renal function (serum creatinine, 0.8 mg/dl and creatinine clearance, 120 ml/h). Opthalmological evaluation confirmed GVHD syndrome involving both eyes, as a sicca-like syndrome. He was treated with prednisone (40 mg daily) with clinical improvement. Two months later, he presented with a total 24-h urine protein of 14.5 g/dl and serum albumin of 1.79 g/dl, pleural effusion, elevation of hepatic enzymes and colestasis (AST, 200 U/l; ALT, 448 U/l; ALP 756 U/l; GGT, 50 IU/l; total bilirubin 1.2 U/l). Serology for hepatitis B and C virus was negative, as were CMV antigen levels (monoclonal antibodies against pt65-core virus protein). Cyclosporine was started (3.5 mg/kg twice daily) and resulted in decreasing proteinuria, regression of pleural effusions and absence of antinuclear antibodies, while hepatic colestasis (ALT, 207 U/l; AST, 88 U/l; ALP, 700 U/l; GGT, 439 U/l) was maintained as the only sign of GVHD.
The patient was treated with CsA and prednisone (20 mg/day) for 8 months and, currently, he has no clinical or laboratory features of GVHD, a negative 24-h urine protein and normal hepatic enzymes and renal function (serum creatinine 0.8 mg/dl; urea nitrogen 28 mg/dl; AST 40 U/l; ALT 38 U/l; GGT 37 U/l; ALP 337 U/l; total bilirubin 1.8 U/l).
During his illness he underwent two liver and renal biopsies, the first at diagnosis and the second 5 months later.
Pathologic features
On light microscopy, the features of the first renal biopsy were compatible with minimal change nephrotic syndrome. There were eight normal glomeruli. Glomerular tufts contained dilated capillaries, glomerular basement membrane was not thickened and glomerular cellularity was within the normal range, with swollen and prominent visceral epithelial cells. Tubular and interstitial blood vessels were unremarkable. The second biopsy showed features consistent with focal and segmental glomerular sclerosis. The biopsy included 12 glomeruli, with the presence of localized areas of sclerosis in two of them. These are as occurred in the Hilary location and collapse of capillaries, expansion of the mesangial matrix and adhesion to Bowman's capsule were present. The remaining part of the biopsy showed features similar to the first one (Figures 1  and 2 ). On electron microscopy, focal effacement of the foot processes and electron dense deposits on basement glomerular membranes were observed (Figure 3) . Liver biopsy showed the histological findings of GVHD; immunohistochemistry for hepatisis virus B infection (HBsAg and HBcAg) was negative.
Discussion
We describe a patient who underwent BMT for AAS and who received CsA plus MTX as GVHD prophylaxis. He developed NS after CsA withdrawal, as his first manifestation of chronic GVHD. He differs from previous reports, where NS was preceded by acute GVHD. He was treated with prednisone without clinical improvement and developed pleural effusions, progressive colestasis and proteinuria. After 2 weeks of CsA, he experienced a remarkable improvement of both NS and GVHD. It is well established that immunological factors are involved in the development of GVHD such as: (1) donor T-lymphocyte cytokine release which may change glomerular permeability; and (2) minor disparities between donor and recipient MHC, responsible for the GVHD phenomenon as a whole. 8, 9 The clear improvement of NS is due to CsA inhibition of interleukin and interferon gamma production by donor T-lymphocytes, which may be responsible for the glomerular permeability alterations in NS.
The seccond biopsy, performed 5 months later, showed segmental sclerosis and also membranous nephropathy. Although auto-antibodies have not been consistently present in all cases described in the literature, circulating or in situ immune complexes are responsible for the features of membranous nephropathy as demonstrated here. However, cellular mechanisms may be implicated as segmental sclerosis also was seen. Immunosuppression can easily control these manifestations and follow-up of such patients requires careful evaluation of their immunological status and CsA should be always tapered slowly to avoid the immune-mediated problems described above.
